Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Kidney Cancer | Research

Genome instability-related long non-coding RNA in clear renal cell carcinoma determined using computational biology

Authors: Yutao Wang, Kexin Yan, Linhui Wang, Jianbin Bi

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

There is evidence that long non-coding RNA (lncRNA) is related to genetic stability. However, the complex biological functions of these lncRNAs are unclear.

Method

TCGA - KIRC lncRNAs expression matrix and somatic mutation information data were obtained from TCGA database. “GSVA” package was applied to evaluate the genomic related pathway in each samples. GO and KEGG analysis were performed to show the biological function of lncRNAs-mRNAs. “Survival” package was applied to determine the prognostic significance of lncRNAs. Multivariate Cox proportional hazard regression analysis was applied to conduct lncRNA prognosis model.

Results

In the present study, we applied computational biology to identify genome-related long noncoding RNA and identified 26 novel genomic instability-associated lncRNAs in clear cell renal cell carcinoma. We identified a genome instability-derived six lncRNA-based gene signature that significantly divided clear renal cell samples into high- and low-risk groups. We validated it in test cohorts. To further elucidate the role of the six lncRNAs in the model’s genome stability, we performed a gene set variation analysis (GSVA) on the matrix. We performed Pearson correlation analysis between the GSVA scores of genomic stability-related pathways and lncRNA. It was determined that LINC00460 and LINC01234 could be used as critical factors in this study. They may influence the genome stability of clear cell carcinoma by participating in mediating critical targets in the base excision repair pathway, the DNA replication pathway, homologous recombination, mismatch repair pathway, and the P53 signaling pathway.

Conclusion subsections

These data suggest that LINC00460 and LINC01234 are crucial for the stability of the clear cell renal cell carcinoma genome.
Appendix
Available only for authorised users
Literature
4.
go back to reference Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic Performance of DWI for Differentiating High- From Low-Grade Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2017;209:W374–374W381.CrossRefPubMed Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic Performance of DWI for Differentiating High- From Low-Grade Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2017;209:W374–374W381.CrossRefPubMed
10.
24.
go back to reference Wang Y, Lin J, Yan K, Wang J. Identification of a robust five-gene risk model in prostate Cancer: a robust likelihood-based survival analysis. Int J Genomics. 2020;2020:1097602.PubMedPubMedCentral Wang Y, Lin J, Yan K, Wang J. Identification of a robust five-gene risk model in prostate Cancer: a robust likelihood-based survival analysis. Int J Genomics. 2020;2020:1097602.PubMedPubMedCentral
25.
go back to reference Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353–353D361.CrossRefPubMed Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353–353D361.CrossRefPubMed
26.
go back to reference Jachimowicz RD, Beleggia F, Isensee J, Velpula BB, Goergens J, Bustos MA, et al. UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. Cell. 2019;176:505–19.e22.CrossRefPubMed Jachimowicz RD, Beleggia F, Isensee J, Velpula BB, Goergens J, Bustos MA, et al. UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. Cell. 2019;176:505–19.e22.CrossRefPubMed
29.
go back to reference Liu Y, Gou X, Wei Z, Yu H, Zhou X, Li X. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma. Aging (Albany NY). 2020;12:15359–73.CrossRef Liu Y, Gou X, Wei Z, Yu H, Zhou X, Li X. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma. Aging (Albany NY). 2020;12:15359–73.CrossRef
38.
go back to reference Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, et al. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol. 2015;35:Suppl:S5–5S24.CrossRefPubMed Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, et al. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol. 2015;35:Suppl:S5–5S24.CrossRefPubMed
39.
42.
go back to reference Scherer D, Deutelmoser H, Balavarca Y, Toth R, Habermann N, Buck K, et al. Polymorphisms in the angiogenesis-related genes EFNB2, MMP2 and JAG1 are associated with survival of colorectal Cancer patients. Int J Mol Sci. 2020;21(15). https://doi.org/10.3390/ijms21155395. Scherer D, Deutelmoser H, Balavarca Y, Toth R, Habermann N, Buck K, et al. Polymorphisms in the angiogenesis-related genes EFNB2, MMP2 and JAG1 are associated with survival of colorectal Cancer patients. Int J Mol Sci. 2020;21(15). https://​doi.​org/​10.​3390/​ijms21155395.
58.
go back to reference Wang S, Zhang L, Tao L, Pang L, Fu R, Fu Y, et al. Construction and investigation of an LINC00284-associated regulatory network in serous ovarian carcinoma. Dis Markers. 2020;2020:9696285.PubMedPubMedCentral Wang S, Zhang L, Tao L, Pang L, Fu R, Fu Y, et al. Construction and investigation of an LINC00284-associated regulatory network in serous ovarian carcinoma. Dis Markers. 2020;2020:9696285.PubMedPubMedCentral
64.
go back to reference Ma J, Han LN, Song JR, Bai XM, Wang JZ, Meng LF, et al. Long noncoding RNA LINC01234 silencing exerts an anti-oncogenic effect in esophageal cancer cells through microRNA-193a-5p-mediated CCNE1 downregulation. Cell Oncol (Dordr). 2020;43:377–94.CrossRef Ma J, Han LN, Song JR, Bai XM, Wang JZ, Meng LF, et al. Long noncoding RNA LINC01234 silencing exerts an anti-oncogenic effect in esophageal cancer cells through microRNA-193a-5p-mediated CCNE1 downregulation. Cell Oncol (Dordr). 2020;43:377–94.CrossRef
65.
go back to reference Zhu Y, Luo C, Korakkandan AA, Fatma Y, Tao Y, Yi T, et al. Function and regulation annotation of up-regulated long non-coding RNA LINC01234 in gastric cancer. J Clin Lab Anal. 2020;34:e23210.PubMedPubMedCentral Zhu Y, Luo C, Korakkandan AA, Fatma Y, Tao Y, Yi T, et al. Function and regulation annotation of up-regulated long non-coding RNA LINC01234 in gastric cancer. J Clin Lab Anal. 2020;34:e23210.PubMedPubMedCentral
67.
go back to reference Chaudhary R, Wang X, Cao B, De La Iglesia J, Masannat J, Song F, et al. Long noncoding RNA, LINC00460, as a prognostic biomarker in head and neck squamous cell carcinoma (HNSCC). Am J Transl Res. 2020;12(2):684–96.PubMedPubMedCentral Chaudhary R, Wang X, Cao B, De La Iglesia J, Masannat J, Song F, et al. Long noncoding RNA, LINC00460, as a prognostic biomarker in head and neck squamous cell carcinoma (HNSCC). Am J Transl Res. 2020;12(2):684–96.PubMedPubMedCentral
Metadata
Title
Genome instability-related long non-coding RNA in clear renal cell carcinoma determined using computational biology
Authors
Yutao Wang
Kexin Yan
Linhui Wang
Jianbin Bi
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08356-9

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine